How does 4018's PE Ratio compare to its peers?

4018 is expensive based on its Price-To-Earnings Ratio (97.9x) compared to the peer average (27.5x).

How does 4018's PE Ratio compare vs other companies in the SA Healthcare Industry?

4018 is expensive based on its Price-To-Earnings Ratio (97.9x) compared to the SA Healthcare industry average (29.2x).

What is 4018's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 4018's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of 4018 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

4018 (SAR133.8) is trading below our estimate of [[fair value]] (SAR188.19)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

4018 Stock Overview

Operates as a private healthcare provider in Saudi Arabia. More details

4018 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	1/6
Financial Health	0/6
Dividends	0/6

Rewards

Trading at 28.9% below our estimate of its fair value

Revenue is forecast to grow 22.76% per year

Risk Analysis

Interest payments are not well covered by earnings

Shares are highly illiquid

Earnings have declined by 4.7% per year over past 5 years

Profit margins (5.3%) are lower than last year (9.2%)

My Notes

Capture your thoughts, links and company narrative

Almoosa Health Company Competitors

Middle East Healthcare

SASE:4009

ر.س6.7b

National Medical Care

SASE:4005

ر.س7.4b

Al Hammadi Holding

SASE:4007

ر.س6.5b

Dallah Healthcare

SASE:4004

ر.س14.8b

Price History & Performance

Summary of share price highs, lows and changes for Almoosa Health
Historical stock prices
Current Share Price	ر.س133.20
52 Week High	ر.س165.00
52 Week Low	ر.س132.40
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-8.77%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	4018	SA Healthcare	SA Market
7D	n/a	3.5%	-0.3%
1Y	n/a	-4.0%	-10.3%

Return vs Industry: Insufficient data to determine how 4018 performed against the SA Healthcare industry.

Return vs Market: Insufficient data to determine how 4018 performed against the SA Market.

Price Volatility

Is 4018's price volatile compared to industry and market?
4018 volatility
4018 Average Weekly Movement	n/a
Healthcare Industry Average Movement	4.8%
Market Average Movement	3.7%
10% most volatile stocks in SA Market	7.9%
10% least volatile stocks in SA Market	2.2%

Stable Share Price: 4018's share price has been volatile over the past 3 months compared to the SA market.

Volatility Over Time: Insufficient data to determine 4018's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1996	2,884	Malek Abdulaziz Al Moosa	almoosahealthgroup.org

Almoosa Health Company operates as a private healthcare provider in Saudi Arabia. The company stores medical items; and sells medicines, cosmetics, and disposable medical items. It also operates hospitals and pharmacies; and provides acute care, active rehabilitation, long-term care, and home healthcare services, as well as healthcare education services.

Almoosa Health Company Fundamentals Summary

How do Almoosa Health's earnings and revenue compare to its market cap?
4018 fundamental statistics
Market cap	ر.س5.90b
Earnings (TTM)	ر.س60.58m
Revenue (TTM)	ر.س1.14b

97.4x

P/E Ratio

5.2x

P/S Ratio

Is 4018 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4018 income statement (TTM)
Revenue	ر.س1.14b
Cost of Revenue	ر.س790.75m
Gross Profit	ر.س352.28m
Other Expenses	ر.س291.71m
Earnings	ر.س60.58m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	1.37
Gross Margin	30.82%
Net Profit Margin	5.30%
Debt/Equity Ratio	194.1%

How did 4018 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/12 10:09
End of Day Share Price	2025/01/09 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Almoosa Health Company is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ibrahim Elaiwat	Aljazira Capital Company